$Ensysce Biosciences(ENSC.US)$Ensysce Biosciences Announces The Co May Continue Its Listing On The Nasdaq Capital Market Tier With An Extension To May 13, 2024 In Order To Demonstrate Compliance With The Equity Requirement In Listing Rule 5550(b)(1) Benzinga· 4 mins ago
In an unprecedented move towards improving opioid safety, Ensysce Biosciences Inc. recently announced a successful meeting with the U.S. Food and Drug Administration (FDA) regarding its next-generation opioid, PF614-MPAR. This pivotal development not only marks a significant milestone for Ensysce but could also have far-reaching implications for the entirety of the opioid industry.$Ensysce Biosciences(ENSC.US)$ ...
$Ensysce Biosciences(ENSC.US)$Ensysce Biosciences Receives FDA Guidance For PF614-MPAR Program Benzinga· 2 mins ago The meeting focused on the Company's non-clinical program for the combination product that is designed for the treatment of severe pain. The FDA provided helpful feedback and advice on non-clinical studies that are required for eventual new drug application (NDA) submission and approval. The guidance will aid in streamlining the development plans for this innovative drug candi...
Ensysce Biosciences股票討論區
Update
Benzinga· 4 mins ago
Ensysce Biosciences Makes Strides in Opioid Overdose Protection with Successful FDA Meeting for PF614-MPAR.
...
News
Benzinga· 2 mins ago
The meeting focused on the Company's non-clinical program for the combination product that is designed for the treatment of severe pain. The FDA provided helpful feedback and advice on non-clinical studies that are required for eventual new drug application (NDA) submission and approval. The guidance will aid in streamlining the development plans for this innovative drug candi...
staying right here
ZERO BORROW, SSR LIST TODAY
Wow that jumped
暫無評論